Current Environment:

Lindsay Frazier | Medical Services


Programs & Services


  • English

Lindsay Frazier | Education

Medical School

Dartmouth Medical School

1984, Hanover, NH



Boston Children's Hospital

1985, Boston, MA



Boston Children's Hospital

Boston, MA


Pediatric Hematology-Oncology

Boston Children's Hospital/Dana-Farber Cancer Institute

1989, Boston, MA

Graduate School

Harvard School of Public Health

1993, Boston, MA

Lindsay Frazier | Certifications

  • American Board of Pediatrics (Hematology-Oncology)

Lindsay Frazier | Professional History

Dr. A. Lindsay Frazier’s clinical focus within pediatric oncology is germ cell tumors (GCT). Her involvement in germ cell tumors ranges from clinical trials, to biology and to epidemiology. She has served on the steering committee of the Childrens’ Oncology Group’s (COG) germ cell committee since 1996 and assumed leadership of the committee in 2007 which entails oversight of all current protocols and development of the strategic initiatives for future protocols across the spectrum of disease from low risk to high risk to salvage therapies.. She has served as the Chair of the COG protocol for low/intermediate risk germ cell tumors protocol (AGCT0132), Vice-Chair of the COG protocol for relapsed germ cell tumors and for high risk germ cell tumors. She has authored numerous papers and chapters on pediatric germ cell tumors and is currently editing a book for Springer of Pediatric Germ Cell Tumors. Dr. Frazier led the formation of an international group of germ cell tumor specialists from the United States and United Kingdom, “MaGIC—the Malignant Germ Cell International Collaboration”  that has merged their clinical trial data from the past 25 years to create a more comprehensive risk classification system now serving as the basis for next generation of international clinical trials currently under review. MaGIC has recently been expanded to include the clinical trial data of the Gynecologic Oncology Group (ovarian GCT) and the Medical Research Council (testicular cancer) so that this risk classification can be developed spanning the adolescent-young adult boundaries. The clinical data can also now be linked to banked biologic specimens. Drs. Frazier and Amatruda have already successfully collaborated on several translational projects utilizing these datasets. Dr. Frazier also holds an appointment in epidemiology at the Harvard School of Public Health and until 2011 served as the co-director of the Growing Up Today Study, a national cohort study of 27,000 offspring of the women in the Nurses Health Study. Her epidemiologic expertise is of use in the design of the design and interpretation of the data generated by this trial.

Lindsay Frazier | Publications